The ATO plus ATRA combination also demonstrated preclinical activity against NPM1 mutant AML cells [37,38], and clinical trials with this combination are currently under way in non-APL AML patients, including in NPM1 mutant AML (clinical trials identifiers NCT03031249 and NCT05297123). This evidence concerns the gene NPM1 and acute promyelocytic leukemia.